Universal Biosensors Inc (ASX: UBI) Share Price and News

Mr Coleman is an experienced investment and funds management executive. His career of 30 years has spanned banking and finance, corporate advisory and funds management. Craig is currently the Executive Chairman of Viburnam Funds. During his executive career, Mr Coleman has held a number of senior executive positions with ANZ Banking Group Ltd, including Managing Director Banking Products, Managing Director Wealth Management, Non-Executive Director E TRADE Australia Ltd and Head of Retail Banking New Zealand. Mr Coleman currently retains non-executive directorship position with publicly listed entity Bell Financial Group Limited and is Chairman of Pacific Star Network Limited.

Ms Smith is experienced investment and funds management executive. During her career, Ms Smith has worked in a number of investment management roles in the funds management industry, where she has been responsible for evaluating and investing in listed and unlisted companies. Ms Smith was formerly the Head of Private Equity at IFM Investors and Chair of the IFM Risk Committee. Ms Smith was also a member of the IFM Investments Committee, a role she has retained following her retirement from the firm. Prior to her role at IFM, Ms Smith held investment management roles including more than a decade at National Mutual Funds Management Ltd (NMFM). At NMFM, she managed Australian equity research and strategy, as well as Australian equity portfolios. Ms Smith is a member of the Audit Committee of the Australian Renewable Energy Authority. She is a trustee director of industry superannuation fund, LUCRF and the Chairperson of the LUCRF Investment Committee. She is a member of the advisory committee for the SA Venture Capital Fund. She is also a board member of Scale Investors Ltd. In July 2018, Ms Smith was appointed to the board of Funds S4.

Mr. Hoey has more than 25 years' experience in technology financing and commercialization. Mr. Hoey is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development. Mr. Mr. Hoey is currently Chief Executive Office and a director of Vaxxas, Inc. During his career Mr. Hoey has worked in management and leadership roles in the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey served as vice president of business development at PathoGenetix, Inc.

Mr McLean has more than 20 years' business and corporate governance experience and is an experienced senior executive leader with service in the medical technology industry in Australia, Asia and US, most recently with Stryker Corporation ('Stryker') as President Asia Pacific. Whilst at Stryker, Mr McLean led a transformation of Asia Pacific to renew growth in Japan and China and led an accelerated growth strategy for Australia/New Zealand. Prior to his time with Stryker, Mr McLean was Lion Nathan's Finance Director International/Business Development and Director Group Risk Assurance & Audit. Since 2021, Mr McLean has served as an Independent Director and Chairman of the Audit and Risk Committee at both Suicide Prevention Australia and also is an Advisor to Bain & Company. He has also previously served on industry boards in Australia (Medical Technology Association of Australia), Japan (American Medical Devices & Diagnostics Manufacturers Association) and Asia Pacific where he was Vice Chairman of the Asia Pacific Medical Technology Association. Mr McLean has - Delivered a recovery for Stryker's business in Japan; Rebuilt the Stryker China business with an investment and talent plan; Extended market leadership and share gains in Australia/New Zealand; restructured Lion Nathan's international operations to set springboard for further international growth; and Introduced risk management systems to Lion Nathan Board, which enabled strategic and operational decisions in China, wine and non-core businesses. He has completed 3 Executive Leadership Programmes (Harvard Business School).

-

-

-

-